Palomar Medical Technologies and Reliant Technologies Announce Launch of a Fractional Technology Licensi...( Program to Offer Licenses to Fund...),Health

Program to Offer Licenses to Fundamental Fractional Patent Families

BURLINGTON, Mass., Nov. 11 /PRNewswire-FirstCall/ -- Palomar Medical Technologies, Inc. (Nasdaq: PMTI) and Reliant Technologies, Inc., today announced the formation of a Fractional Technology Open Patent Program ("FTOPP") to offer licenses in the professional field to key intellectual property in the fractional space. The FTOPP contains six fundamental fractional patent families including issued patents and pending patent applications owned or controlled by Palomar, Reliant and Massachusetts General Hospital ("MGH"). In addition to this program Palomar and Reliant have entered into certain cross-licenses between the two companies.

Fractional light-based treatments deliver laser or high-powered light energy in a pattern that leaves untreated areas of skin between the treated areas of skin. The healthy, untreated areas promote faster healing of the treated areas and stimulate increased clinical response as compared to standard full surface treatments. Clinical studies show fractional treatments can increase both efficacy and safety.

Fractional treatments have quickly become one of the most widely accepted and sought after new dermatology treatments. In response, many companies have launched new fractional products to meet the large market demand.

As pioneers of fractional technology, Palomar, Reliant and MGH are the owners of the fundamental intellectual property in this area. In order to encourage further development of fractional products while also seeking compensation for their early, ground breaking work, Palomar, Reliant and MGH have created the FTOPP to provide others in the industry the opportunity to license the necessary intellectual pr
'/>"/>